News

OneSource Specialty Pharma announced that its partner Dr. Reddy`s Laboratories has received a Notice of Compliance from Health Canada for Semaglutide Injection, a generic version of Ozempic�. OneSource serves as the CDMO partner on this program, providing scale-up and manufacturing support. The partnership is designed to ensure reliable and scalable commercial supply from OneSource`s US-FDA approved flagship manufacturing facility in Bengaluru.Neeraj Sharma, CEO & MD, OneSource Speciality Pharma Limited, speaking on the development, said: �We are pleased to announce that our partner Dr. Reddy`s has received approval from Health Canada for Semaglutide Injection, a generic version of Ozempic�. This approval further strengthens our collaboration, combining Dr. Reddy`s expertise in peptide development with OneSource`s CDMO capabilities.�

OneSource Speciality Pharma announced that its partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval for an Abbreviated New Drug Application (ANDA) for a generic version of Ozempic� (Semaglutide Injection). OneSource is the contract development and manufacturing organization (CDMO) partner for this product. This milestone highlights a closely integrated development-to-submission model: Orbicular led the product development and technical program for this complex peptide, while OneSource supported the program as the CDMO partner, providing end-to-end manufacturing capabilities for the U.S. market filing. The collaboration is designed to ensure reliable commercial supply from OneSource`s US-FDA approved flagship site in Bangalore. Neeraj Sharma, CEO & MD, OneSource Speciality Pharma, speaking on the development, said: �We are pleased to announce that our partner Orbicular, along with its front-end partner (the ANDA holder), has received tentative approval for a generic version of Ozempic� (Semaglutide Injection). This milestone reflects Orbicular`s scientific expertise and OneSource`s CDMO capabilities, supported by our US-FDA approved manufacturing site.�

OneSource Specialty Pharma announced that NSE Sustainability Ratings & Analytics has, independently assigned Environmental, Social and Governance (�ESG`) Rating of �73` (Rating Category: Leader) to the company for the financial year FY25.

OneSource Speciality Pharma announced it has received Saudi Food and Drug Authority (SFDA) approval of its generic Ozempic� (semaglutide) in Saudi Arabia, clearing the path for commercialsing the product with Hikma Pharmaceuticals PLC (Hikma) as their exclusive commercialisation partner for the Middle East and North Africa (MENA).The approval represents an important entry for OneSource into the Kingdom of Saudi Arabia, one of the largest markets for GLP-1 therapies, positioning the exclusive partnership to capitalise on rising demand for this product and underscoring the shared ambition of both companies to increase access to high-quality affordable generic alternatives to patients across the region.Under the exclusive agreement, OneSource will manufacture and supply semaglutide from its state of-the-art integrated Biologics and Drug-Device Combination facility in Bengaluru and Hikma, the largest pharmaceutical company in MENA based on sales1, will use its extensive commercial reach and institutional relationships in the region to scale access across both private and institutional channels.Powered by Capital Market - Live News

Net Loss of OneSource Specialty Pharma reported to Rs 88.70 crore in the quarter ended December 2025 as against net loss of Rs 68.85 crore during the previous quarter ended December 2024. Sales declined 26.04% to Rs 290.34 crore in the quarter ended December 2025 as against Rs 392.56 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales290.34392.56 -26 OPM %5.9736.14 - PBDT-16.28102.78 PL PBT-85.9234.02 PL NP-88.70-68.85 -29 Powered by Capital Market - Live News